Focus on increased serum angiotensin-converting enzyme level: From granulomatous diseases to genetic mutations

Lopez‐Sublet, Marilucy; Lanzacco, Lorenzo Caratti di; Danser, A.H. Jan; Lambert, Michel; Elourimi, G.; Persu, Alexandre

doi:10.1016/j.clinbiochem.2018.06.010

Cited by 27 publications

(13 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NO generated from eNOS drops off with age, and patients with chronic vascular inflammation, such as in type 2 diabetes, metabolic syndrome, chronic obstructive pulmonary disease, obesity, autoimmune disorders and hemoglobinopathies, may produce less eNOS [ 34 , 39 , 40 ]. Additionally, ACE activity relative to ACE2 activity may be elevated in patients with chronic vascular inflammation [ 41 , 42 ]. Older patients with vascular stressors from underlying chronic medical conditions may exhibit inadequate vascular NO levels, increasing their vulnerability to H/R and I/R injury.…”

Section: The Rationale For Nitric Oxide Usementioning

confidence: 99%

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

et al. 2020

View full text Add to dashboard Cite

The ongoing outbreak of COVID-19 has quickly become a daunting challenge to global health. In the absence of targeted therapy and a reported 5.5% case fatality rate in the United States, treatments preventing rapid cardiopulmonary failure are urgently needed. Clinical features, pathology and homology to better understood pathogens suggest that uncontrolled inflammation and a cytokine storm likely drive COVID-19's unrelenting disease process. Interventions that are protective against acute lung injury and ARDS can play a critical role for patients and health systems during this pandemic. Nitric oxide is an antimicrobial and anti-inflammatory molecule with key roles in pulmonary vascular function in the context of viral infections and other pulmonary disease states. This article reviews the rationale for exogenous nitric oxide use for the pathogenesis of COVID-19 and highlights its potential for contributing to better clinical outcomes and alleviating the rapidly rising strain on healthcare capacity.

show abstract

Section: The Rationale For Nitric Oxide Usementioning

confidence: 99%

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…В нашем исследовании была определена концентрация A II в СЖ, причем было Таблица. Концентрация АII, АПФ и ММП-9 в сыворотке крови и слезной жидкости у пациентов с диабетической ретинопатией и в контрольной группе Table. Сoncentrations of angiotensin II, angiotensin-converting enzyme and matrix metalloprotease-9 in tears and patients serum of with diabetic retinopathy and in control group АП, пг/мл / АП, pg/ml АПФ, нг/мл / ACE, ng/ml ММП-9, нг/мл / MMP-9, ng/ml АПФ инактивирует брадикинин [17], который является прямым вазодилататором и усиливает высвобождение таких сосудорасширяющих веществ, как монооксид азота и простациклин. Кроме того, брадикинин стимулирует выброс гистамина из тучных клеток, синтез и высвобождение простагландинов, ряда интерлейкинов и фактора некроза опухоли в различных тканях, способствует процессам репарации, обладает инсулиноподобным действием, стимулируя захват глюкозы периферическими тканями, модулирует передачу нервных импульсов в центральной и периферической нервной системе [18].…”

Section: Discussionunclassified

Variation of Concentrations of Angiotensin II, AngiotensinConverting Enzyme and Matrix Metalloprotease-9 in Tears and Serum of Patients with Diabetic Retinopathy

et al. 2020

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is becoming more and more widespread disease. Investigation of local changes of metabolic pathways in the eye improves our knowledge about diabetic retinopathy pathogenesis and provide perspective for the development of new pathogenetically based and individually focused therapy of this disease.Purpose of the study was to determine the concentrations of angiotensin II (AII), angiotensin-converting enzyme (ACE) and matrix metalloprotease-9 (MMP-9) in tears and serum of patients with diabetic retinopathy, estimate their significance for the evaluation of diabetic retinopathy severity and choice of treatment.Patients and methods. Tear and serum samples from 31 patients with diabetic retinopathy were analysed. Control group consisted of healthy volunteers of the same sex and age. Concentrations of angiotensin II, angiotensin-converting enzyme and matrix metalloprotease-9 were measured using the ELISA kits.Results: in controls angiotensin II concentration was 9.8 ± 5.5 pg/ml, in tears — 11.8 ± 6.6 pg/ml, angiotensin-converting enzyme concentration in serum was 82.6 ± 10.9 ng/ml, in tears it was 40 times lower: 2.5 ± 0.5 ng/ml, matrix metalloprotease-9 concentration in serum was 186.3 ± 8.9 ng/ml while in tears it was 100 times lower: 2.0 ± 0.9 ng/ml. In tears of patients with diabetic retinopathy levels of all 3 substances were significantly higher than in controls. Concentration of angiotensin II was 8 times higher, angiotensin-converting enzyme concentration 5 times higher and matrix metalloprotease-9 level 3 times higher. In serum angiotensin II concentration was increased 9 times, angiotensin-converting enzyme — 2 times. No difference in serum matrix metalloprotease-9 levels was observed. Thus diabetic retinopathy cause a significant activation of local and systemic rennin-angiotensin system. Local changes are more marked than systemic. Estimation of angiotensin II, angiotensin-converting enzyme and matrix metalloprotease-9 concentrations in tears can serve as an objective test for the diabetic retinopathy diagnostic and a pathogenetic rationale for the development of a new method of therapy — topical use of angiotensin-converting enzyme inhibitors.

show abstract

“…Besides serum, ACE activity has also been assessed in bronchoalveolar lavage (BAL) fluid, cerebrospinal fluid (CSF) and urine of patients with sarcoidosis, with elevation described in the former two biological fluids [ [18] , [19] , [20] ]. Insertion/deletion (I/D) polymorphisms of the ACE gene and angiotensin II receptor 1 (AT2R1) gene are confounding factors that can affect SACE activity [ [21] , [22] , [23] ]. Therefore, evaluation of SACE activity can be improved by genotyping patients for ACE I/D polymorphisms.…”

Section: Methodsmentioning

confidence: 99%

Serum angiotensin converting enzyme, Erythrocyte sedimentation rate and high sensitive-C reactive protein levels in diagnosis of cardiac sarcoidosis- where do we stand?

Bera

Naidu

Saggu

et al. 2020

Indian Pacing and Electrophysiology Journal

View full text Add to dashboard Cite

Background Cardiac sarcoidosis (CS) is increasingly being recognized in the last two decades. The diagnosis of CS depends on clustering of multiple symptoms, investigations and demonstration of a non-caseating granuloma on histopathology. Serum Angiotensin Converting Enzyme (SACE) level, one of the serological markers, is often elevated in systemic sarcoidosis. However, the yield of SACE level among patients with isolated or predominant CS is unclear. We conducted a retrospective study to assess the prevalence of elevated SACE level among patients with proven CS. Materials and methods From our Granulomatous myocarditis (GM) registry, 45 biopsy proven CS patients were enrolled. Inclusion criteria : Clinical diagnosis of CS [HRS definition + Lymph Node biopsy/Endomyocardial biopsy (non-caseating granuloma)]. Exclusion criteria - Other causes of GM like cardiac tuberculosis (TB culture/AFB smear -positive) and patients taking medications affecting SACE level. Results Among 143 GM cases, 45 CS were analyzed. Mean age:42 ± 11 years (Range 22–63 years, 19 females). With our laboratory reference of SACE (Normal range: 20–70 U/L), 3 out of 45 (6.7%) patients of CS had elevated SACE. In a comparative analysis we found, Erythrocyte Sedimentation Rate (ESR) and High sensitive-C Reactive Protein (Hs-CRP) are much more sensitive, although not specific for CS. Patients with pulmonary involvement more often had elevated SACE level. Conclusion Serum ACE is elevated only in approximately 6.7% of patients with biopsy proven CS. Hence, it is insensitive serological tool for diagnosis of CS even in the active phase of the disease. In contrast, ESR and Hs-CRP emerges to be more sensitive markers of active CS.

show abstract

Focus on increased serum angiotensin-converting enzyme level: From granulomatous diseases to genetic mutations

Cited by 27 publications

References 60 publications

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19

Variation of Concentrations of Angiotensin II, AngiotensinConverting Enzyme and Matrix Metalloprotease-9 in Tears and Serum of Patients with Diabetic Retinopathy

Serum angiotensin converting enzyme, Erythrocyte sedimentation rate and high sensitive-C reactive protein levels in diagnosis of cardiac sarcoidosis- where do we stand?

Contact Info

Product

Resources

About